Identification of the potential Pan-CDK antagonists: tracing the path of virtual screening and inhibitory activity on lung cancer cells
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-10939-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Jia-Hao Tao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Basic Medical Science, Central South University, Changsha, 410078, Hunan, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Protein Kinase Inhibitors, Cyclin-Dependent Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Hunan Provincial Innovation Foundation for Postgraduate, Postgraduate Innovative Project of Central South University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cyclin-dependent kinases (CDKs) are overexpressed in tumor cells, and their aberrant activation can promote the progression of non-small-cell lung cancer (NSCLC). We utilized structure-based virtual screening and experimental validation to screen for potential CDKs antagonists among TargetMol natural products. Molecular docking and molecular dynamics simulation results indicate that Dolastatin 10 exhibits strong interactions with multiple subtypes of CDKs (CDK1, CDK2, CDK3, CDK4, and CDK6), forming stable CDKs-Dolastatin 10 complex compounds. Furthermore, in vitro experiments demonstrate that Dolastatin 10 significantly inhibits the viability, migration, and invasion of H1299 cells in a concentration-dependent manner, arresting the cell cycle at the G2/M phase by inducing cell senescence. These findings suggest that Dolastatin 10 may serve as a potential CDKs antagonist deserving further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Basic Medical Science, Central South University, Changsha, 410078, Hunan, China.
- Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, Changsha, 410078, Hunan, China.
- Ascle Therapeutics, Suzhou, 215000, Jiangsu, China.
- Department of Physiology, School of Basic Medical Science, Central South University, Changsha, 410078, Hunan, China. zhouyong421@csu.edu.cn.
- Department of Physiology, School of Basic Medical Science, Central South University, Changsha, 410078, Hunan, China. guanchaxiang@csu.edu.cn.
Förderung
- Hunan Provincial Innovation Foundation for Postgraduate
- Postgraduate Innovative Project of Central South University
- National Natural Science Foundation of China
- Fundamental Research Funds for Central Universities of the Central South University
Zitieren
APA
Tao, J. H., Ruan, P. L., Zhang, J., Zhou, Y., & Guan, C. X. (2025). Identification of the potential Pan-CDK antagonists: tracing the path of virtual screening and inhibitory activity on lung cancer cells. Molecular Diversity. https://doi.org/10.1007/s11030-024-10939-0
Vancouver
Tao JH, Ruan PL, Zhang J, Zhou Y, Guan CX. Identification of the potential Pan-CDK antagonists: tracing the path of virtual screening and inhibitory activity on lung cancer cells. Molecular Diversity. 2025. doi:10.1007/s11030-024-10939-0
BibTeX
@article{Tao2025,
author = {Tao, Jia-Hao and Ruan, Ping-Lang and Zhang, Jun and Zhou, Yong and Guan, Cha-Xiang},
title = {Identification of the potential Pan-CDK antagonists: tracing the path of virtual screening and inhibitory activity on lung cancer cells},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-10939-0}
}
EUVIMED